# VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies

> **NCT03885947** · PHASE1 · COMPLETED · sponsor: **Alla Keyzner** · enrollment: 7 (actual)

## Conditions studied

- Hematological Malignancy
- Acute Leukemia in Remission
- Acute Lymphoblastic Leukemia in Remission
- Myelodysplastic Syndromes
- Non-Hodgkin Lymphoma
- Hodgkin Lymphoma

## Interventions

- **BIOLOGICAL:** Cord blood stem cells
- **DRUG:** Valproic Acid
- **DRUG:** Fludarabine
- **DRUG:** cytoxan
- **DRUG:** Thiotepa
- **BIOLOGICAL:** TBI

## Key facts

- **NCT ID:** NCT03885947
- **Lead sponsor:** Alla Keyzner
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-21
- **Primary completion:** 2021-03-10
- **Final completion:** 2021-03-10
- **Target enrollment:** 7 (ACTUAL)
- **Last updated:** 2021-05-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03885947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03885947, "VPA Expanded UCB Transplantation for Treatment of Patients With Hematological Malignancies". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT03885947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*